Plus Therapeutics Inc

Plus Therapeutics insider moves: CFO buys, CEO sells; static hold by the development chief. Discover what the next clinical data release could mean for stock volatility and investor confidence.

Plus Therapeutics insider trades reveal CEO’s long‑term commitment via RSUs while selling shares for liquidity—analyzing how this balance impacts investor confidence and the company’s biopharma pipeline.

Plus Therapeutics CFO’s insider buy of RSUs and options signals bullish confidence in the company’s CPT‑code expansion and future revenue growth.